149 related articles for article (PubMed ID: 18725510)
1. The molecular basis of CYP2D6-mediated N-dealkylation: balance between metabolic clearance routes and enzyme inhibition.
Bonn B; Masimirembwa CM; Aristei Y; Zamora I
Drug Metab Dispos; 2008 Nov; 36(11):2199-210. PubMed ID: 18725510
[TBL] [Abstract][Full Text] [Related]
2. Coumarin substrates for cytochrome P450 2D6 fluorescence assays.
Nakamura K; Hanna IH; Cai H; Nishimura Y; Williams KM; Guengerich FP
Anal Biochem; 2001 May; 292(2):280-6. PubMed ID: 11355862
[TBL] [Abstract][Full Text] [Related]
3. Influence of N-substitution of 7-methoxy-4-(aminomethyl)-coumarin on cytochrome P450 metabolism and selectivity.
Venhorst J; Onderwater RC; Meerman JH; Commandeur JN; Vermeulen NP
Drug Metab Dispos; 2000 Dec; 28(12):1524-32. PubMed ID: 11095593
[TBL] [Abstract][Full Text] [Related]
4. Phe120 contributes to the regiospecificity of cytochrome P450 2D6: mutation leads to the formation of a novel dextromethorphan metabolite.
Flanagan JU; Maréchal JD; Ward R; Kemp CA; McLaughlin LA; Sutcliffe MJ; Roberts GC; Paine MJ; Wolf CR
Biochem J; 2004 Jun; 380(Pt 2):353-60. PubMed ID: 14992686
[TBL] [Abstract][Full Text] [Related]
5. The role of phenylalanine 483 in cytochrome P450 2D6 is strongly substrate dependent.
Lussenburg BM; Keizers PH; de Graaf C; Hidestrand M; Ingelman-Sundberg M; Vermeulen NP; Commandeur JN
Biochem Pharmacol; 2005 Oct; 70(8):1253-61. PubMed ID: 16135359
[TBL] [Abstract][Full Text] [Related]
6. Role of the conserved threonine 309 in mechanism of oxidation by cytochrome P450 2D6.
Keizers PH; Schraven LH; de Graaf C; Hidestrand M; Ingelman-Sundberg M; van Dijk BR; Vermeulen NP; Commandeur JN
Biochem Biophys Res Commun; 2005 Dec; 338(2):1065-74. PubMed ID: 16269134
[TBL] [Abstract][Full Text] [Related]
7. Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms.
Yu A; Kneller BM; Rettie AE; Haining RL
J Pharmacol Exp Ther; 2002 Dec; 303(3):1291-300. PubMed ID: 12438554
[TBL] [Abstract][Full Text] [Related]
8. Characterization of dextromethorphan O- and N-demethylation catalyzed by highly purified recombinant human CYP2D6.
Yu A; Dong H; Lang D; Haining RL
Drug Metab Dispos; 2001 Nov; 29(11):1362-5. PubMed ID: 11602510
[TBL] [Abstract][Full Text] [Related]
9. Functional analysis of CYP2D6.31 variant: homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution.
Allorge D; Bréant D; Harlow J; Chowdry J; Lo-Guidice JM; Chevalier D; Cauffiez C; Lhermitte M; Blaney FE; Tucker GT; Broly F; Ellis SW
Proteins; 2005 May; 59(2):339-46. PubMed ID: 15726636
[TBL] [Abstract][Full Text] [Related]
10. Expression, purification, and characterization of mouse CYP2d22.
Yu AM; Haining RL
Drug Metab Dispos; 2006 Jul; 34(7):1167-74. PubMed ID: 16595712
[TBL] [Abstract][Full Text] [Related]
11. A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6.
de Groot MJ; Ackland MJ; Horne VA; Alex AA; Jones BC
J Med Chem; 1999 Oct; 42(20):4062-70. PubMed ID: 10514276
[TBL] [Abstract][Full Text] [Related]
12. CYP2D6-Mediated metabolism of a novel acyl coenzyme A:cholesterol acyltransferase inhibitor, pactimibe, and its unique plasma metabolite, R-125528.
Kotsuma M; Tokui T; Ishizuka-Ozeki T; Honda T; Iwabuchi H; Murai T; Ikeda T; Saji H
Drug Metab Dispos; 2008 Mar; 36(3):529-34. PubMed ID: 18056254
[TBL] [Abstract][Full Text] [Related]
13. Role of glutamic acid 216 in cytochrome P450 2D6 substrate binding and catalysis.
Guengerich FP; Hanna IH; Martin MV; Gillam EM
Biochemistry; 2003 Feb; 42(5):1245-53. PubMed ID: 12564927
[TBL] [Abstract][Full Text] [Related]
14. Identification of human cytochrome p450 isozymes involved in diphenhydramine N-demethylation.
Akutsu T; Kobayashi K; Sakurada K; Ikegaya H; Furihata T; Chiba K
Drug Metab Dispos; 2007 Jan; 35(1):72-8. PubMed ID: 17020955
[TBL] [Abstract][Full Text] [Related]
15. Influence of phenylalanine-481 substitutions on the catalytic activity of cytochrome P450 2D6.
Hayhurst GP; Harlow J; Chowdry J; Gross E; Hilton E; Lennard MS; Tucker GT; Ellis SW
Biochem J; 2001 Apr; 355(Pt 2):373-9. PubMed ID: 11284724
[TBL] [Abstract][Full Text] [Related]
16. Validation of model of cytochrome P450 2D6: an in silico tool for predicting metabolism and inhibition.
Kemp CA; Flanagan JU; van Eldik AJ; Maréchal JD; Wolf CR; Roberts GC; Paine MJ; Sutcliffe MJ
J Med Chem; 2004 Oct; 47(22):5340-6. PubMed ID: 15481972
[TBL] [Abstract][Full Text] [Related]
17. Structure-based site of metabolism prediction for cytochrome P450 2D6.
Moors SL; Vos AM; Cummings MD; Van Vlijmen H; Ceulemans A
J Med Chem; 2011 Sep; 54(17):6098-105. PubMed ID: 21797232
[TBL] [Abstract][Full Text] [Related]
18. Binding of bufuralol, dextromethorphan, and 3,4-methylenedioxymethylamphetamine to wild-type and F120A mutant cytochrome P450 2D6 studied by resonance Raman spectroscopy.
Bonifacio A; Keizers PH; Commandeur JN; Vermeulen NP; Robert B; Gooijer C; van der Zwan G
Biochem Biophys Res Commun; 2006 May; 343(3):772-9. PubMed ID: 16563352
[TBL] [Abstract][Full Text] [Related]
19. The in vitro inhibitory potential of trade herbal products on human CYP2D6-mediated metabolism and the influence of ethanol.
Hellum BH; Nilsen OG
Basic Clin Pharmacol Toxicol; 2007 Nov; 101(5):350-8. PubMed ID: 17910620
[TBL] [Abstract][Full Text] [Related]
20. Topological role of cytochrome P450 2D6 active site residues.
van Waterschoot RA; Keizers PH; de Graaf C; Vermeulen NP; Tschirret-Guth RA
Arch Biochem Biophys; 2006 Mar; 447(1):53-8. PubMed ID: 16466686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
